Efficacy and Safety Results of the Afatinib Expanded Access Program

INTRODUCTION: Afatinib is an oral, irreversible ErbB family blocker approved for first-line treatment of metastatic epidermal growth factor receptor (EGFR) mutation–positive non–small cell lung cancer (NSCLC). The expanded access program (EAP) allowed early access to afatinib and provided additional...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncol Ther
Autores principales: Kim, Edward S., Halmos, Balazs, Kohut, Ingrid F., Patel, Taral, Rostorfer, Regan D., Spira, Alexander I., Cseh, Agnieszka, McKay, John, Wallenstein, Gudrun, Mileham, Kathryn F.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Healthcare 2017
Materias:
Brief Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5488108/
https://ncbi.nlm.nih.gov/pubmed/28680960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-017-0043-5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares